


Generic Lidex Ointment by Lupin receives FDA approval

03 August 2017 | News

Lidex Ointment had US sales of USD 40.3 million



Pharma company Lupin Limited has announced that United States Food and Drug Administration (USFDA) has finally approved its Fluocinonide Topical Ointment USP, 0.05% to market a generic version of County Line Pharmaceuticals, LLC's Lidex Ointment, 0.05%.

Indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, Lupin's Fluocinonide Topical Ointment USP, 0.05% is AB rated generic equivalent of LLC's Lidex Ointment, 0.05%.

Lidex Ointment had US sales of USD 40.3 million (IMS MAT March 2017).